 |
인쇄하기
취소
|
Novacell Technology develops novel biomarker that may accurately diagnose breast cancer
Novacell Technology said yesterday it has created a new biomarker NCB102 that is considered to a highly accurate method of obtaining a preoperative histological diagnosis of breast cancer showing a resistance to Roche’s Herceptin.
Recently, the company conducted a clinical test in a local university hospital, with an aim to evaluate predictive factors of breast carcinoma on NCB102.
The st...
Recently, the company conducted a clinical test in a local university hospital, with an aim to evaluate predictive factors of breast carcinoma on NCB102.
The st...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.